{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:19:35Z","timestamp":1789906775519,"version":"4.0.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.intimp.2023.110643","type":"journal-article","created":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T14:51:45Z","timestamp":1689346305000},"page":"110643","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Ascorbic acid and IFN\u03b3 preconditioning enhance the potency of human mesenchymal stem cells to ameliorate LPS induced cytokine storm"],"prefix":"10.1016","volume":"122","author":[{"given":"Avinash","family":"Sanap","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supriya","family":"Kheur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avinash","family":"Kharat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Bhonde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.intimp.2023.110643_b0005","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.immuni.2020.05.002","article-title":"Immunology of COVID-19: Current State of the Science","volume":"52","author":"Vabret","year":"2020","journal-title":"Immunity. [Internet]."},{"issue":"1","key":"10.1016\/j.intimp.2023.110643_b0010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.immuni.2020.06.017","article-title":"Cytokine Storms: Understanding COVID-19","volume":"53","author":"Mangalmurti","year":"2020","journal-title":"Immunity. [Internet]."},{"issue":"June","key":"10.1016\/j.intimp.2023.110643_b0015","first-page":"1","article-title":"The COVID-19 Cytokine Storm; What We Know So Far","volume":"11","author":"Ragab","year":"2020","journal-title":"Front. Immunol."},{"issue":"May","key":"10.1016\/j.intimp.2023.110643_b0020","first-page":"1","article-title":"Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019","volume":"11","author":"Wu","year":"2020","journal-title":"Front. Immunol."},{"issue":"Figure 1","key":"10.1016\/j.intimp.2023.110643_b0025","article-title":"Mesenchymal stem cell treatment for COVID-19","volume":"77","author":"Xu","year":"2022","journal-title":"eBioMedicine. [Internet]."},{"key":"10.1016\/j.intimp.2023.110643_b0030","article-title":"Mesenchymal stem cells: from experiment to clinic","volume":"4(1):20","author":"Wright","year":"2011","journal-title":"Fibrogenesis. Tissue. Repair. [Internet]."},{"issue":"2","key":"10.1016\/j.intimp.2023.110643_b0035","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/cdd.2013.158","article-title":"Immunobiology of mesenchymal stem cells","volume":"21","author":"Ma","year":"2014","journal-title":"Cell. Death. Differ."},{"key":"10.1016\/j.intimp.2023.110643_b0040","first-page":"12(July)","article-title":"Regulation of Inflammatory Cytokine Storms by Mesenchymal Stem Cells","author":"Wang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2023.110643_b0045","doi-asserted-by":"crossref","unstructured":"A. Mizukami, K. Swiech, Mesenchymal stromal cells: From discovery to manufacturing and commercialization. Stem Cells Int., 2018, 2018.","DOI":"10.1155\/2018\/4083921"},{"key":"10.1016\/j.intimp.2023.110643_b0050","article-title":"Potential pre-activation strategies for improving therapeutic efficacy of mesenchymal stem cells: current status and future prospects","volume":"13(1):146","author":"Li","year":"2022","journal-title":"Stem. Cell. Res. Ther. [Internet]."},{"issue":"1","key":"10.1016\/j.intimp.2023.110643_b0055","first-page":"1","article-title":"Enhancement strategies for mesenchymal stem cells and related therapies","volume":"13","author":"Alagesan","year":"2022","journal-title":"Stem. Cell. Res. Ther. [Internet]."},{"key":"10.1016\/j.intimp.2023.110643_b0060","doi-asserted-by":"crossref","unstructured":"S.R. Ahmad, Vitamin C for COVID-19 Treatment\u00a0: Have We Got Enough Evidence\u00a0? 2022;9(May):19\u201322.","DOI":"10.3389\/fnut.2022.892561"},{"key":"10.1016\/j.intimp.2023.110643_b0065","doi-asserted-by":"crossref","unstructured":"Natasa Todorovic-Rakovic JRW b a. Between immunomodulation and immunotolerance: The role of IFN\u03b3 in SARS-CoV-2 disease. Cytokine. 2021;146.","DOI":"10.1016\/j.cyto.2021.155637"},{"key":"10.1016\/j.intimp.2023.110643_b0070","doi-asserted-by":"crossref","unstructured":"D. Sharma, F. Zhao, Updates on clinical trials evaluating the regenerative potential of allogenic mesenchymal stem cells in COVID-19. npj Regen Med [Internet]. 2021;6(1). Available from: http:\/\/dx.doi.org\/10.1038\/s41536-021-00147-x.","DOI":"10.1038\/s41536-021-00147-x"},{"issue":"3","key":"10.1016\/j.intimp.2023.110643_b0075","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1111\/jcmm.13492","article-title":"Preconditioning influences mesenchymal stem cell properties in vitro and in vivo","volume":"22","author":"Hu","year":"2018","journal-title":"J. Cell. Mol. Med."},{"issue":"10","key":"10.1016\/j.intimp.2023.110643_b0080","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/stem.698","article-title":"Pretreatment with interferon-\u03b3 enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis","volume":"29","author":"Duijvestein","year":"2011","journal-title":"Stem. Cells."},{"issue":"1","key":"10.1016\/j.intimp.2023.110643_b0085","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/mt.2011.189","article-title":"Human MSC Suppression Correlates With Cytokine Induction of Indoleamine 2, 3-Dioxygenase and Bystander M2 Macrophage Differentiation","volume":"20","author":"Fran\u00e7ois","year":"2012","journal-title":"Mol. Ther."},{"issue":"22","key":"10.1016\/j.intimp.2023.110643_b0090","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1089\/scd.2013.0028","article-title":"IFN-\u03b3 stimulated human umbilical-tissue-derived cells potently suppress NK activation and resist NK-mediated cytotoxicity in vitro","volume":"22","author":"Noone","year":"2013","journal-title":"Stem. Cells. Dev."},{"issue":"3","key":"10.1016\/j.intimp.2023.110643_b0095","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12015-014-9495-2","article-title":"Interferon-Gamma Modification of Mesenchymal Stem Cells: Implications of Autologous and Allogeneic Mesenchymal Stem Cell Therapy in Allotransplantation","volume":"10","author":"Sivanathan","year":"2014","journal-title":"Stem. Cell. Rev. Reports."},{"issue":"4","key":"10.1016\/j.intimp.2023.110643_b0100","article-title":"Vitamin C and COVID-19","volume":"7","author":"Hemil\u00e4","year":"2021","journal-title":"Front. Med."},{"issue":"7","key":"10.1016\/j.intimp.2023.110643_b0105","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11070589","article-title":"Effect of ascorbic acid on differentiation, secretome and stemness of stem cells from human exfoliated deciduous tooth (Sheds)","volume":"11","author":"Bhandi","year":"2021","journal-title":"J. Pers. Med."},{"issue":"1","key":"10.1016\/j.intimp.2023.110643_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-018-0825-1","article-title":"Evaluation of the effects of ascorbic acid on metabolism of human mesenchymal stem cells","volume":"9","author":"Fujisawa","year":"2018","journal-title":"Stem. Cell. Res. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2023.110643_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-022-02797-0","article-title":"Ascorbic acid 2-glucoside preconditioning enhances the ability of bone marrow mesenchymal stem cells in promoting wound healing","volume":"13","author":"Yi","year":"2022","journal-title":"Stem. Cell. Res. Ther."},{"issue":"11","key":"10.1016\/j.intimp.2023.110643_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nu9111211","article-title":"Vitamin C and immune function","volume":"9","author":"Carr","year":"2017","journal-title":"Nutrients."},{"issue":"6","key":"10.1016\/j.intimp.2023.110643_b0125","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41577-021-00553-8","article-title":"Is IL-6 a key cytokine target for therapy in COVID-19?","volume":"21","author":"Jones","year":"2021","journal-title":"Nat. Rev. Immunol. [Internet]."},{"issue":"1","key":"10.1016\/j.intimp.2023.110643_b0130","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12879-021-05945-8","article-title":"Role of interleukin 6 as a predictive factor for a severe course of Covid-19: retrospective data analysis of patients from a long-term care facility during Covid-19 outbreak","volume":"21","author":"Sabaka","year":"2021","journal-title":"BMC. Infect. Dis."},{"issue":"5","key":"10.1016\/j.intimp.2023.110643_b0135","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2213-2600(21)00081-3","article-title":"Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial","volume":"9","author":"Soin","year":"2021","journal-title":"Lancet. Respir. Med. [Internet]."},{"issue":"5","key":"10.1016\/j.intimp.2023.110643_b0140","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S2213-2600(21)00099-0","article-title":"Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Lescure","year":"2021","journal-title":"Lancet. Respir. Med."},{"issue":"7","key":"10.1016\/j.intimp.2023.110643_b0145","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23073673","article-title":"What Is Currently Known about the Role of CXCL10 in SARS-CoV-2 Infection?","volume":"23","author":"Gudowska-Sawczuk","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"May","key":"10.1016\/j.intimp.2023.110643_b0150","first-page":"1","article-title":"Features of Cytokine Storm Identified by Distinguishing Clinical Manifestations in COVID-19","volume":"9","author":"Shen","year":"2021","journal-title":"Front. Public. Heal."},{"issue":"January","key":"10.1016\/j.intimp.2023.110643_b0155","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cytogfr.2020.05.003","article-title":"The cytokine storm in COVID-19: An overview of the involvement of the chemokine\/chemokine-receptor system","volume":"53","author":"Coperchini","year":"2020","journal-title":"Cytokine. Growth. Factor. Rev."},{"issue":"10","key":"10.1016\/j.intimp.2023.110643_b0160","doi-asserted-by":"crossref","DOI":"10.3390\/cells10102588","article-title":"Mesenchymal stem cells in the treatment of covid-19, a promising future","volume":"10","author":"Beghini","year":"2021","journal-title":"Cells."},{"issue":"3","key":"10.1016\/j.intimp.2023.110643_b0165","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s12015-020-09973-w","article-title":"Mesenchymal Stem Cell Therapy for COVID-19: Present or Future","volume":"16","author":"Golchin","year":"2020","journal-title":"Stem. Cell. Rev. Reports."},{"key":"10.1016\/j.intimp.2023.110643_b0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.57555","article-title":"Kallikrein-kinin blockade in patients with covid-19 to prevent acute respiratory distress syndrome","volume":"9","author":"van de Veerdonk","year":"2020","journal-title":"Elife."},{"issue":"12","key":"10.1016\/j.intimp.2023.110643_b0175","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/bmt.2009.75","article-title":"Optimal use of G-CSF administration after hematopoietic SCT","volume":"43","author":"Trivedi","year":"2009","journal-title":"Bone Marrow Transplant [Internet]."},{"issue":"1","key":"10.1016\/j.intimp.2023.110643_b0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-25191-5","article-title":"The cytokines HGF and CXCL13 predict the severity and the mortality in COVID-19 patients","volume":"12","author":"Perreau","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2023.110643_b0185","doi-asserted-by":"crossref","unstructured":"A. Sanap, B. Chandravanshi, T. Shah, G. Tillu, A. Dhanushkodi, R. Bhonde, et al. Herbal pre-conditioning induces proliferation and delays senescence in Wharton\u2019s Jelly Mesenchymal Stem Cells. Biomed Pharmacother [Internet]. 2017;93:772\u20138. Available from: http:\/\/dx.doi.org\/10.1016\/j.biopha.2017.06.107.","DOI":"10.1016\/j.biopha.2017.06.107"},{"issue":"11","key":"10.1016\/j.intimp.2023.110643_b0190","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1002\/cbin.11051","article-title":"Establishment of an in ovo chick embryo yolk sac membrane (YSM) assay for pilot screening of potential angiogenic and anti-angiogenic agents","volume":"42","author":"Muhammad Nihad","year":"2018","journal-title":"Cell Biol Int."},{"key":"10.1016\/j.intimp.2023.110643_b0195","doi-asserted-by":"crossref","unstructured":"S. Tumpara, A.R. Gr\u00fcnding, K. Sivaraman, S. Wrenger, B. Olejnicka, T. Welte, et al. Boosted Pro-Inflammatory Activity in Human PBMCs by Lipopolysaccharide and SARS-CoV-2 Spike Protein Is Regulated by \u03b1 -1 Antitrypsin \u2020. 2021.","DOI":"10.3390\/ijms22157941"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923009682?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923009682?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T14:26:27Z","timestamp":1736432787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923009682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":39,"alternative-id":["S1567576923009682"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110643","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ascorbic acid and IFN\u03b3 preconditioning enhance the potency of human mesenchymal stem cells to ameliorate LPS induced cytokine storm","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110643","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110643"}}